C12N 2810/857
From blood coagulation or fibrinolysis factors
Official title: from blood coagulation or fibrinolysis factors
C12N2810/857 (From blood coagulation or fibrinolysis factors) appears on 11 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 18
- Assignees
- 5
- Inventors
- 21
- Latest grant
- 28 Oct 2014
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 0 |
| 2005 | 2 | 1 |
| 2006 | 1 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 2 | 1 |
| 2011 | 0 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 0 |
| 2015 | 0 | 1 |
By publication year.
Recent patents
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury28 Oct 2014US 8,871,734 B2University of Southern California
- Method for transfer of gene into fat cell or progenitor fat cell16 Sep 2014US 8,835,177 B2Takara Bio Inc.
- Targeted vectors for cancer immunotherapy9 Sep 2014US 8,828,378 B2University of Southern California
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury10 Sep 2013US 8,530,441 B2University of Southern California
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury3 Apr 2012US 8,148,509 B2University of Southern California
- Targeted vectors for cancer immunotherapy29 Jan 2015US 2015/0031625 A1University of Southern California
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury12 Dec 2013US 2013/0331547 A1Epeius Biotechnologies Corporation
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury1 Nov 2012US 2012/0276052 A1University of Southern California
- Targeted nanoparticles for cancer and other disorders2 Feb 2012US 2012/0027727 A1Epeius Biotechnologies Corporation
- Modulation of Adenoviral Tropism5 May 2011US 2011/0104788 A1
Most cited
By later US patents
- Targeted adenovirus vectors for delivery of heterologous genes22US 6,911,199 B2Aventis Pharma S. A. · 2005
- Method of delivering therapeutic agents to site of tissue injury12US 7,347,998 B2University of Southern California · 2008
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury12US 7,820,157 B2University of Southern California · 2010
- Modified viral surface proteins for binding to extracellular matrix components5US 6,864,082 B2University of Southern California · 2005
- Transgene delivering retrovirus targeting collagen exposed at site of tissue injury5US 8,530,441 B2University of Southern California · 2013